Hidradenitis suppurativa (HS) is a multifactorial disease characterized by the progression of nodules to deep-seated lesions, with subsequent scarring and suppuration. [1][2][3][4] The exact etiology of HS is still unproven.Multiple therapies have been described, including topical, systemic, surgical, and physical treatments. 1,5,6 At present, topical HS therapy include cleansers, keratolytic agents, and antibiotics. 7 Androgens are implicated in skin physiology and may have a role in HS worsening. 8 Consequently, the administration of systemic antiandrogen therapy were described in a small population. 5,8 To the best of our knowledge, this is the first study that describes topical antiandrogen therapy in HS. Here we describe 4 patients that received a commercially available topical finasteride on 2-3 HS affected sites at dosage 50 μl of 2275 mg/ml for each area (Table 1). Patients did not alter their hygiene or antiseptic habits during topical finasteride application.Case 1: A 28-year-old man affected by HS for 12 years, with lesions in axillae, gluteal and inguinal region. He received multiple HS treatments with disease recurrence and discontinuation (Table 1).Recently he experienced frequent inflammatory episodes of three nodules in the left axilla and one nodule in the right axilla. Disease severity 1,9 was: Hurley II, international HS severity (IHS4): 6, dermatology life quality index (DLQI): 16. Daily topical finasteride was introduced on both axillae. Three months later, a significant improvement was observed (IHS4: 2, DLQI: 8, Figure 1A-D).